Trial Profile

A Phase 2 Clinical Trial to Evaluate KarXT (Trospium-chloride/xanomeline) in Dementia-Related Psychosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trospium chloride/xanomeline (Primary)
Indications Dementia
Focus Therapeutic Use
Sponsors Karuna Therapeutics

Most Recent Events

23 Jun 2021 According to a Karuna Therapeutics media release, this trial is planned to initiate in first half of 2022
04 Mar 2021 New trial record
26 Feb 2021 According to a Karuna Therapeutics media release, planning for this Phase 2 trial in dementia-related psychosis has commenced and the Company expects to provide further guidance following the completion of Cohort 3 of the phase Ib trial (CTP 309092) later this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com